Feb 02, 2023
RNS Number : 7153O MaxCyte, Inc. 02 February 2023   MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences   ROCKVILLE, MD , February 2, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering
Jan 30, 2023
RNS Number : 2143O MaxCyte, Inc. 30 January 2023   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Exercise of options, PDMR dealing and Total Voting Rights   ROCKVILLE, MD , January 30, 2023  -   MaxCyte (NASDAQ: MXCT; LSE: MXCT), a   leading commercial cell   -   engineering company focused on
Jan 04, 2023
RNS Number : 5691L MaxCyte, Inc. 04 January 2023         MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs   MaxCyte's Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell